Biocon Biologics and Viatris to offer insulin glargine injection at a discounted price

Members can save up to 80 per cent off the cash price of comparable long-acting insulins purchased at Walgreens

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, and Viatris Inc confirm that Insulin Glargine injection will be offered through the Walgreens Prescription Savings Club, saving members up to 80 per cent off the cash price of comparable long-acting insulins purchased at Walgreens. 

This decision by Walgreens follows the launch of Insulin Glargine announced on November 16. Biocon Biologics and Viatris co-developed the product, and together the companies are committed to improving patients' access to sustainable, quality and more affordable healthcare. 

Biocon Biologics and Viatris are committed to ensuring that the interchangeable biosimilar insulin glargine can reach as many patients as possible regardless of financial circumstances, insurance or channel. The collaboration with Walgreens underscores efforts to improve outcomes and access for patients by meeting the needs of cash-paying patients and partnering with key stakeholders across the country to lower out-of-pocket costs for insulin users. 

Biocon Biologics has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Five molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like the United States, EU, Australia, Canada and Japan. With a team of 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients worldwide. 

The share closed at Rs 366.80, down by 2.68 per cent on November 18, 2021.